Background/Aims: Lipoprotein glomerulopathy (LPG) is a rare disease characterized by thrombus-like substances in markedly dilated glomerular capillaries and elevated plasma levels of apolipoprotein E (apoE). Previous studies have shown that genetic disorders of apoE may contribute to the pathogenesis of LPG, but LPG may not be caused by apoE gene mutations in Chinese patients. This study investigated the association of a new variant of apoE with LPG in a Chinese family. Methods: The apoE gene in a family with 4 LPG patients was sequenced. The polymerase chain reaction product of coding region of apoE exon 4 was cloned into pMD 18-T vector and then sequenced. Results: A novel point mutation in exon 4 of the apoE gene was identified in all 4 LPG patients and 1 asymptomatic family member. Sequence analysis confirmed a nucleotide G to C point mutation in exon 4 (base 308) of the apoE gene in all patients and the asymptomatic family member. This missense mutation denotes amino acid substitution of the proline residue for arginine residue at position 150 of apoE. Those patients were all heterozygotes with apoE Guangzhou. One of 2 grandsons was a heterozygous carrier of apoE Guangzhou, although he did not have proteinuria. Conclusion: The results of this study suggest that apoE (arginine 150 proline) is a novel apoE variant that etiologically related to LPG. This variant (apoE Guangzhou) may cause a marked molecular conformational change of the apoE and thus impair its binding ability to lipids.

Keywords:
Lipoprotein glomerulopathy, Apolipoprotein E, Nephrotic syndrome, Gene mutation
1.
Saito T, Sato H, Kudo K, Oikawa S, Shibata T, Hara Y, Yoshinaga K, Sakaguchi H: Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis 1989;13:148–153.
2.
Watanabe Y, Ozaki I, Yoshida F, Fukatsu A, Itoh Y, Matsuo S, Sakamoto N: A case of nephrotic syndrome with glomerular lipoprotein deposition with capillary ballooning and mesangiolysis. Nephron 1989;51:265–270.
3.
Saito T, Sato H, Oikawa S, Kudo K, Kurihara I, Nakayama K, Abe K, Yoshinaga K, Sakaguchi H: Lipoprotein glomerulopathy. Report of a normolipidemic case and review of the literature. Am J Nephrol 1993;13:64–68.
4.
Sam R, Wu H, Yue L, Mazzone T, Schwartz MM, Arruda JA, Dunea G, Singh AK: Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis 2006;47:539–548.
5.
Shaw DJ, Brook JD, Meredith AL, Harley HG, Sarfarazi M, Harper PS: Gene mapping and chromosome 19. J Med Genet 1986;23:2–10.
6.
Liberopoulos E, Siamopoulos K, Elisaf M: Apolipoprotein E and renal disease. Am J Kidney Dis 2004;43:223–233.
7.
Marcel YL, Kiss RS: Structure-function relationships of apolipoprotein A-I: a flexible protein with dynamic lipid associations. Curr Opin Lipidol 2003;14:151–157.
8.
Oikawa S, Matsunaga A, Saito T, Sato H, Seki T, Hoshi K, Hayasaka K, Kotake H, Midorikawa H, Sekikawa A, Hara S, Abe K, Toyota T, Jingami H, Nakamura H, Sasaki J: Apolipoprotein E Sendai (arginine 145→proline): a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol 1997;8:820–823.
9.
Matsunaga A, Sasaki J, Komatsu T, Kanatsu K, Tsuji E, Moriyama K, Koga T, Arakawa K, Oikawa S, Saito T, Kita T, Doi T: A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int 1999;56:421–427.
10.
Ando M, Sasaki J, Hua H, Matsunaga A, Uchida K, Jou K, Oikawa S, Saito T, Nihei H: A novel 18-amino-acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. Kidney Int 1999;56:1317–1323.
11.
Konishi K, Saruta T, Kuramochi S, Oikawa S, Saito T, Han H, Matsunaga A, Sasaki J: Association of a novel 3-amino-acid deletion mutation of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy. Nephron 1999;83:214–218.
12.
Ogawa T, Maruyama K, Hattori H, Arai H, Kondoh I, Egashira T, Watanabe T, Kobayashi Y, Morikawa A: A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy. Pediatr Nephrol 2000;14:149–151.
13.
Chen S, Liu ZH, Zheng JM, Zhang X, Li LS: A complete genomic analysis of the apolipoprotein E gene in Chinese patients with lipoprotein glomerulopathy. J Nephrol 2007;20:568–575.
14.
Ishigaki Y, Oikawa S, Suzuki T, Usui S, Magoori K, Kim DH, Suzuki H, Sasaki J, Sasano H, Okazaki M, Toyota T, Saito T, Yamamoto TT: Virus-mediated transduction of apolipoprotein E (ApoE)-Sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. J Biol Chem 2000;275:31269–31273.
15.
Mahley RW: Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622–630.
16.
Lalazar A, Weisgraber KH, Rall SC Jr, Giladi H, Innerarity TL, Levanon AZ, Boyles JK, Amit B, Gorecki M, Mahley RW, et al: Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J Biol Chem 1988;263:3542–3545.
17.
Hoffmann M, Scharnagl H, Panagiotou E, Banghard W, Wieland H, Marz W: Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J Am Soc Nephrol 2001;12:524–530.
18.
Elshourbagy NA, Liao WS, Mahley RW, Taylor JM: Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci USA 1985;82:203–207.
19.
Saito T, Oikawa S, Sato H, Sato T, Ito S, Sasaki J: Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features. Kidney Int suppl 1999;71:S37–S41.
20.
Djamali A, Cristol JP, Turc-Baron C, Beucler I, Baldet P, Mourad G: Lipoprotein glomerulopathy: a new French case with recurrence on the transplant (in French). Presse Med 1996;25:798–802.
21.
Mourad G, Cristol JP, Turc-Baron C, Djamali A: Lipoprotein glomerulopathy: a new apolipoprotein-E-related disease that recurs after renal transplantation. Transplant Proc 1997;29:2376.
22.
Andrews PA, O’Donnell PJ, Dilly SA, Snowden SA, Bewick M: Recurrence of lipoprotein glomerulopathy after renal transplantation. Nephrol Dial Transplant 1997;12:2442–2444.
23.
Miyata T, Sugiyama S, Nangaku M, Suzuki D, Uragami K, Inagi R, Sakai H, Kurokawa K: Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney. J Am Soc Nephrol 1999;10:1590–1595.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.